BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; low-dose infigratinib, a treatment option for children living with hypochondroplasia, a skeletal dysplasia closely related to achondroplasia which is in Phase 2/3. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. The company has license and collaboration agreements with the Alexion Pharma International Operations Unlimited Company, Leland Stanford Junior University and Leidos Biomedical Research, Inc., and Novartis International Pharmaceutical Ltd. BridgeBio Pharma, Inc. was founded in 2015 and is headquartered in Palo Alto, California.

BridgeBio Pharma Inc.

Bridgebio Pharma (($BBIO)) has held its Q3 earnings call. Read on for the main highlights of the call. BridgeBio Pharma’s recent earnings call refl...

BridgeBio Pharma’s Earnings Call Highlights Success and Challenges

In a report released today, Biren Amin from Piper Sandler maintained a Buy rating on BridgeBio Pharma, with a price target of $98.00. The company’s...

Piper Sandler Sticks to Their Buy Rating for BridgeBio Pharma (BBIO)

Bridgebio Pharma ( ($BBIO) ) has released its Q3 earnings. Here is a breakdown of the information Bridgebio Pharma presented to its investors. Brid...

BridgeBio Pharma Reports Strong Q3 2025 Results

The latest announcement is out from BridgeBio Pharma ( ($BBIO) ). BridgeBio Pharma announced positive results from its Phase 3 CALIBRATE study of e...

BridgeBio Pharma Reports Positive Phase 3 Study Results

Evercore ISI analyst Cory Kasimov maintained a Buy rating on BridgeBio Pharma today and set a price target of $75.00. The company’s shares opened t...

BridgeBio Pharma (BBIO) Receives a Buy from Evercore ISI

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Urogen Pharma (URGN – Research Report), AngioDynamic...

Market Cap	$12.64B	P/E Ratio	N/A
52W High	$69.48	52W Low	$25.34
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	9.6%	52W Position	96.9%
Overall Score	56	Value Score	40
Quality Score	--	Technical Score	72

EPS Current Est	$-3.47	EPS Next Est	$-1.74
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	BBIO	$68.11	+5.40%	4.13M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	BBIO	$68.11	+5.4%	4.13M
3
4
5
6

BBIO

BBIO

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get BridgeBio Pharma Inc. Data in Excel

Get BridgeBio Pharma Inc. Data in Excel